NCT05584709View on ClinicalTrials.gov

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

STI-6129

Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
lead

Sorrento Therapeutics, Inc.

INDUSTRY

NCT05584709 - Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter